The estimated Net Worth of Jeffrey G. Lamothe is at least $565 Tisíc dollars as of 8 August 2024. Mr Lamothe owns over 314 units of Aptevo Therapeutics Inc stock worth over $421 and over the last 8 years he sold APVO stock worth over $0. In addition, he makes $564,867 as Sr. VP a CFO & Treasurer at Aptevo Therapeutics Inc.
Sign up
Mr Lamothe APVO stock SEC Form 4 insiders trading
Mr has made over 7 trades of the Aptevo Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 314 units of APVO stock worth $113 on 8 August 2024.
The largest trade he's ever made was exercising 13,812 units of Aptevo Therapeutics Inc stock on 8 August 2023 worth over $4,986. On average, Mr trades about 1,352 units every 38 days since 2016. As of 8 August 2024 he still owns at least 1,166 units of Aptevo Therapeutics Inc stock.
You can see the complete history of Mr Lamothe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Jeffrey G. Lamothe biography
Jeffrey G. Lamothe is the Sr. VP, CFO & Treasurer at Aptevo Therapeutics Inc.
What is the salary of Mr Lamothe?
As the Sr. VP a CFO & Treasurer of Aptevo Therapeutics Inc, the total compensation of Mr Lamothe at Aptevo Therapeutics Inc is $564,867. There are 1 executives at Aptevo Therapeutics Inc getting paid more, with Marvin L. White having the highest compensation of $859,495.
How old is Mr Lamothe?
Mr Lamothe is 55, he's been the Sr. VP a CFO & Treasurer of Aptevo Therapeutics Inc since . There are 2 older and no younger executives at Aptevo Therapeutics Inc. The oldest executive at Aptevo Therapeutics Inc is Dr. Jane A. Gross, 63, who is the Sr. VP & Chief Scientific Officer.
What's Mr Lamothe's mailing address?
Jeffrey's mailing address filed with the SEC is 2401 4TH AVENUE, SUITE 1050, SEATTLE, WA, 98121.
Insiders trading at Aptevo Therapeutics Inc
Over the last 8 years, insiders at Aptevo Therapeutics Inc have traded over $17,157,676 worth of Aptevo Therapeutics Inc stock and bought 1,998,342 units worth $25,387,921 . The most active insiders traders include Kevin Ctang Capital Managem..., Fuad El Hibri a Daniel Abdun Nabi. On average, Aptevo Therapeutics Inc executives and independent directors trade stock every 38 days with the average trade being worth of $22,185. The most recent stock trade was executed by So Young Kwon on 8 August 2024, trading 213 units of APVO stock currently worth $77.
What does Aptevo Therapeutics Inc do?
aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.
What does Aptevo Therapeutics Inc's logo look like?
Complete history of Mr Lamothe stock trades at Aptevo Therapeutics Inc
Aptevo Therapeutics Inc executives and stock owners
Aptevo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Marvin L. White,
Pres, CEO & Director -
Jeffrey G. Lamothe,
Sr. VP, CFO & Treasurer -
Dr. Jane A. Gross,
Sr. VP & Chief Scientific Officer -
Dr. Fatih M. Uckun M.D., Ph.D.,
Chief Clinical Advisor & Consultant -
SoYoung Kwon J.D., LL.M.,
Sr. VP, Gen. Counsel, Corp. Affairs & HR -
Censia Pottorf,
VP of HR -
Heather Boussios,
Acting Gen. Counsel & Assistant Sec. -
Stacey Jurchison,
Sr. Director of Investor Relations & Corp. Communications -
Scott C Stromatt,
Chief Medical Officer and SVP -
Fuad El Hibri,
Director -
Bio Solutions Inc. Emergent,
10% owner -
Daphne Taylor,
SVP, CFO -
Zsolt Harsanyi,
-
John Niederhuber,
-
Marvin L White,
President and CEO -
Daniel Abdun Nabi,
-
Grady Iii Grant,
-
Shawnte Mitchell,
SVP, GC and Corporate Affairs -
Michael Adelman,
SVP, Commercial Operations -
Jeffrey G. Lamothe,
EVP, COO -
Jane A Gross,
SVP & Chief Scientific Officer -
Randy Joe Maddux,
SVP of Operations, CMO -
Barbara Lopez Kunz,
-
So Young Kwon,
SVP, GC, BD & Corp Affairs -
Kevin Ctang Capital Managem...,